表面功能化的SERS平台用于深度学习辅助的阿尔茨海默病诊断
Minjoon Kim1, Sejoon Huh2, Hyung Joon Park1
1Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
Biosensors & bioelectronics
|February 17, 2024
概括
这项研究介绍了一种新的深度学习辅助的表面增强拉曼光谱 (SERS) 平台,用于使用血液生物标志物的早期阿尔茨海默病诊断. 该系统通过分析粉样β和代谢物,在区分疾病状态方面实现了高精度.
科学领域:
- 生物医学工程 生物医学工程
- 分析化学 分析化学
- 神经科学是一个神经科学.
背景情况:
- 早期阿尔茨海默病 (AD) 诊断对于减缓认知衰退至关重要.
- 传统的诊断方法是侵入性的或复杂的.
- 无标签的表面增强拉曼光谱 (SERS) 提供了快速的生物流体分析,但由于干扰,在生物标志物特征提取方面面临挑战.
研究的目的:
- 开发一个深度学习辅助的SERS平台,用于对血基粉样β (1-42) 和代谢物进行分离和准确的分析,用于阿尔茨海默病的诊断.
- 制造和功能化SERS基板,以加强对AD生物标志物的检测.
- 用先进的机器学习技术验证平台的诊断能力.
主要方法:
- 使用金 (Au) 纳米线阵列制造SERS基板.
- 用6E10抗体检测粉样β (1-42) 的SERS基质的功能化以及用于代谢物分析的自组合单层.
- 从AD患者和对照者的血中获取SERS光谱.
- 使用深度学习算法对SERS光谱进行分类,并使用可解释的AI进行特征识别.
主要成果:
- 在基于代谢物SERS谱的基础上对阿尔茨海默病患者和对照组进行分类,获得了高精度 (高达99.5%).
- 成功检测和分析了粉样β (1-42) 寡合化过程.
- 用可解释的人工智能识别关键光谱特征进行分类,突出显著生物标志物.
结论:
- 开发的深度学习辅助SERS平台为早期阿尔茨海默病诊断提供了灵敏,非侵入性和准确的方法.
- 这种方法克服了传统诊断和生物流体分析中的光谱干扰的局限性.
- 该平台显示了在阿尔茨海默病检测和生物标志物发现中临床应用的巨大潜力.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189


